Frontiers in Genetics (Mar 2022)
Clinical and Genetic Characteristics of IKZF1 Mutation in Chinese Children With B-Cell Acute Lymphoblastic Leukemia
- Jingying Zhang,
- Jingying Zhang,
- Jingying Zhang,
- Xiao-Jun Xu,
- Xiao-Jun Xu,
- Xiao-Jun Xu,
- Lixia Liu,
- Hua Song,
- Hua Song,
- Hua Song,
- Heping Shen,
- Heping Shen,
- Heping Shen,
- Weiqun Xu,
- Weiqun Xu,
- Weiqun Xu,
- Fenying Zhao,
- Fenying Zhao,
- Fenying Zhao,
- Juan Liang,
- Juan Liang,
- Juan Liang,
- Chan Liao,
- Chan Liao,
- Chan Liao,
- Yan Wang,
- Yan Wang,
- Yan Wang,
- Tian Xia,
- Tian Xia,
- Tian Xia,
- Shanbo Cao,
- Yongmin Tang,
- Yongmin Tang,
- Yongmin Tang,
- Jiayue Qin,
- Diying Shen,
- Diying Shen,
- Diying Shen
Affiliations
- Jingying Zhang
- Division/Center of Pediatric Hematology-Oncology, The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, China
- Jingying Zhang
- The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, Hangzhou, China
- Jingying Zhang
- National Clinical Research Center for Child Health, Hangzhou, China
- Xiao-Jun Xu
- Division/Center of Pediatric Hematology-Oncology, The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, China
- Xiao-Jun Xu
- The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, Hangzhou, China
- Xiao-Jun Xu
- National Clinical Research Center for Child Health, Hangzhou, China
- Lixia Liu
- Acornmed Biotechnology Co., Ltd., Tianjin, China
- Hua Song
- Division/Center of Pediatric Hematology-Oncology, The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, China
- Hua Song
- The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, Hangzhou, China
- Hua Song
- National Clinical Research Center for Child Health, Hangzhou, China
- Heping Shen
- Division/Center of Pediatric Hematology-Oncology, The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, China
- Heping Shen
- The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, Hangzhou, China
- Heping Shen
- National Clinical Research Center for Child Health, Hangzhou, China
- Weiqun Xu
- Division/Center of Pediatric Hematology-Oncology, The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, China
- Weiqun Xu
- The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, Hangzhou, China
- Weiqun Xu
- National Clinical Research Center for Child Health, Hangzhou, China
- Fenying Zhao
- Division/Center of Pediatric Hematology-Oncology, The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, China
- Fenying Zhao
- The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, Hangzhou, China
- Fenying Zhao
- National Clinical Research Center for Child Health, Hangzhou, China
- Juan Liang
- Division/Center of Pediatric Hematology-Oncology, The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, China
- Juan Liang
- The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, Hangzhou, China
- Juan Liang
- National Clinical Research Center for Child Health, Hangzhou, China
- Chan Liao
- Division/Center of Pediatric Hematology-Oncology, The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, China
- Chan Liao
- The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, Hangzhou, China
- Chan Liao
- National Clinical Research Center for Child Health, Hangzhou, China
- Yan Wang
- Division/Center of Pediatric Hematology-Oncology, The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, China
- Yan Wang
- The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, Hangzhou, China
- Yan Wang
- National Clinical Research Center for Child Health, Hangzhou, China
- Tian Xia
- Division/Center of Pediatric Hematology-Oncology, The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, China
- Tian Xia
- The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, Hangzhou, China
- Tian Xia
- National Clinical Research Center for Child Health, Hangzhou, China
- Shanbo Cao
- Acornmed Biotechnology Co., Ltd., Tianjin, China
- Yongmin Tang
- Division/Center of Pediatric Hematology-Oncology, The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, China
- Yongmin Tang
- The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, Hangzhou, China
- Yongmin Tang
- National Clinical Research Center for Child Health, Hangzhou, China
- Jiayue Qin
- Acornmed Biotechnology Co., Ltd., Tianjin, China
- Diying Shen
- Division/Center of Pediatric Hematology-Oncology, The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, China
- Diying Shen
- The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, Hangzhou, China
- Diying Shen
- National Clinical Research Center for Child Health, Hangzhou, China
- DOI
- https://doi.org/10.3389/fgene.2022.822832
- Journal volume & issue
-
Vol. 13
Abstract
Acute lymphoblastic leukemia (ALL) is a malignancy associated with altered lymphoid precursor hyperplasia and accompanied with different genetic mutations. Few studies have been reported on the association between gene mutations and clinical features of IKZF1 mutation in children with B-cell ALL (B-ALL). We investigated clinical and genetic characteristics in 200 newly diagnosed pediatric B-ALL through multiplex ligation-dependent probe amplification (MLPA) and targeted next-generation sequencing (NGS) method. We found that IKZF1 mutations, including large segment deletions, small insertions or deletions (InDels) and single nucleotide variations (SNVs), were detected in 22 patients with a positive mutation rate of 11.0%. IKZF1 mutation was significantly associated with higher WBC count (19.38 × 109/L vs. 5.80 × 109/L, p = 0.002). Compared with IKZF1 wild-type cases, a higher frequency of IL7R gene mutation was discovered in IKZF1 mutant cases (9.1% vs. 0.0%, p = 0.012). Patients with IKZF1 mutation were less sensitive to glucocorticoid induction than patients without IKZF1 mutation (63.6% vs. 9.0%, p < 0.001). On the 15th day of induction, minimal residual disease (MRD) > 10−3 level were higher in IKZF1 mutant patients than wild-type patients (45.5% vs. 22.3%, p = 0.018). In conclusion, our study reveals the association between genetic mutations and clinical features in Chinese children with B-ALL, which might contribute to molecular classification, risk stratification and prognosis evaluation, and provide new ideas for targeted therapy in ALL.
Keywords
- IKZF1 mutation
- B-cell acute lymphoblastic leukemia
- genetic characteristics
- clinical features
- targeted next-generation sequencing